Gene editing is edging closer to delivering one-time treatments that could keep cholesterol in check for decades, potentially replacing daily pills. Clinicians and researchers say the same technology that could transform medicine also demands careful scrutiny over safety, permanence, and unintended effects.
Gene therapy is already in use for certain severe illnesses. These approaches can add functional genes, silence harmful activity, or alter DNA directly. Unlike conventional drugs that require ongoing dosing, some genetic interventions aim to act after a single administration.
Scientists have identified more than 6,000 rare genetic disorders, though only a fraction currently have treatable targets. Gene therapies have notched significant wins against spinal muscular atrophy and sickle cell disease.
Investigators are now testing whether similar strategies could help prevent or manage far more common conditions, including high cholesterol, heart disease, obesity, and diabetes.
That pushes a fundamental question to the fore: even if permanent changes to a person’s genetic activity are possible, should they be made?
In a perspective in JAMA Internal Medicine, University of Michigan Health Frankel Cardiovascular Center cardiologists Eric D. Smith, M.D., and Venkatesh L. Murthy, M.D., Ph.D., outline how clinicians and researchers should balance the promise of genomic therapies with their risks.
The authors describe why these treatments are compelling, how they differ from standard medicines, and what must be in place before they can be offered safely to large populations.
Why gene editing differs from daily medication
A key attraction of gene therapy is the potential for durable benefit without repeated dosing.
Traditional drugs work only while patients continue to take them. Genomic therapies act on the genetic blueprint itself. They may deliver a healthy gene, suppress a gene with harmful effects, or modify a precise DNA sequence.
This opens the door to “one-and-done” treatments designed to work after a single dose.
One treatment, however, does not guarantee lifetime benefit.
Smith notes that many gene therapies use modified viruses to ferry instructions into cells. The immune system can recognize these vectors and mount a response. If benefits wane, re-administering the same product may be difficult or impossible.
Another distinction is which cells are altered. Current gene therapies generally target somatic cells, not germline cells involved in reproduction, so changes are not intended to be inherited by future generations.
Why gene editing common diseases raises new risks
For people with rare, devastating conditions and few options, potential benefits may outweigh dangers, even in early-stage interventions.
The calculus shifts with common diseases.
High cholesterol, heart disease, obesity, and diabetes already have established treatments. Many conventional therapies can be titrated or stopped if side effects emerge.
A permanent genetic change may not offer that flexibility.
Murthy highlights another concern: scale. A rare adverse effect can harm many people if a therapy is used by millions.
Treatments intended for broad use must therefore clear especially stringent safety thresholds.
Five questions scientists say must be answered
Smith and Murthy propose assessing five core factors to determine when genomic therapy is appropriate:
- Disease severity: How serious is the condition, and how much benefit could patients gain?
- Existing treatments: Are there effective options that can be adjusted or discontinued if needed?
- Treatment durability: Is the targeted tissue suitable for a one-time intervention intended to last?
- Delivery risks: Are the hazards of delivering the therapy acceptable given the disease?
- Long-term monitoring: Can safety and effectiveness be tracked reliably over many years, especially at large scale?
The last point may be the most difficult.
Clinical trials usually involve relatively small cohorts followed for limited periods. They can reveal many safety signals, but may miss extremely rare events or late-emerging problems.
Some adverse effects may surface only after widespread use.
The challenge of tracking long-term risks
Smith argues that long-term surveillance must be integral to how gene therapies enter practice, not an afterthought.
Patient registries already show the value of extended follow-up.
But therapies that could reach millions will require monitoring systems that operate at much larger scale.
These systems must be independent and standardized so researchers can consistently evaluate ongoing effectiveness and detect unexpected issues over time.
Without reliable long-horizon data, clinicians may struggle to judge the full consequences of interventions that cannot easily be reversed.
Are some permanent genetic changes too risky?
Another question is whether certain diseases or biological processes are appropriate for irreversible treatment.
Murthy cautions that having the technical ability to alter a genetic target does not automatically make it the right medical choice.
Some conditions require careful dose adjustments over time. In some cases, the line between therapeutic and harmful effects is narrow. Pushing a pathway too far in either direction can cause complications.
Conventional medicines allow clinicians to dial therapy up or down, or to stop altogether.
Permanent gene therapies typically lack that flexibility.
Researchers may eventually engineer genetic “off-switches” or other reversal methods.
Until such tools are proven reliable, the ability to undo or adjust treatment remains a major safety advantage of standard care.
Gene editing and the million-dollar barrier
Safety is not the only hurdle to mainstreaming gene editing. Cost could determine access.
Several approved gene therapies carry list prices above $1 million per patient, with some substantially higher.
Such pricing may be defensible for rare, life-threatening diseases with few alternatives.
Applying similar costs to conditions affecting millions would strain health systems.
Smith and Murthy argue that affordability and access must be central to planning.
Even highly effective therapies could worsen inequities if only a small share of patients can obtain them. Policymakers and researchers must consider not only clinical performance but also whether delivery can be scaled without deepening disparities.
Could one treatment cut heart risk for decades?
Despite the challenges, gene editing aimed at preventing common disease is moving from concept to clinic.
Early studies are testing whether a single intervention can lower LDL, or “bad,” cholesterol for the long term.
LDL drives plaque buildup in arteries, raising the risk of heart attacks and other cardiovascular events. Sustained LDL reduction is a proven strategy to cut risk.
If gene editing can safely deliver durable LDL lowering, it could offer a new way to protect cardiovascular health without indefinite medication.
Encouraging early data will not be enough on its own.
Before such therapies become routine for common conditions, researchers will need strong evidence that benefits persist, long-term risks remain acceptably low, and costs are manageable. Robust safeguards will be essential.
For Smith and Murthy, the goal is not to slow progress but to ensure that a technology with the power to reshape healthcare is introduced carefully and responsibly.
As gene therapy expands beyond rare disorders to conditions affecting millions, the central task will be ensuring that the promise of lasting protection does not compromise long-term patient safety.